, Volume 7, Issue 2 Supplement, pp 833-841
Date: 19 Nov 2013

Pharmacological agents for nonalcoholic steatohepatitis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The rationale for specific pharmacologic therapy in nonalcoholic steatohepatitis (NASH) is determined by the potential for disease progression and the difficulties, in many patients, to successfully implement diet and lifestyle changes in the long term. Because they correct insulin resistance, insulin-sensitizing agents are attractive candidates for the treatment of NASH. However, two randomized studies have shown that vitamin E, despite having no effect on insulin sensitivity, achieves interesting histological and biochemical efficacy. This review provides an insight into the therapeutic efficacy and safety issues of different pharmacological agents tested in human NASH.